Quote | iCo Therapeutics (OTCMKTS:MSCLF)
Last: | $0.32 |
---|---|
Change Percent: | 7.06% |
Open: | $0.2974 |
Close: | $0.32 |
High: | $0.32 |
Low: | $0.2974 |
Volume: | 2,000 |
Last Trade Date Time: | 05/06/2024 03:00:00 am |
News | iCo Therapeutics (OTCMKTS:MSCLF)
2024-04-23 10:29:06 ET More on Edgewise Therapeutics Edgewise Therapeutics: Behind The Massive Rally Krystal Biotech, Candel, Edgewise gain after FDA fast track tags Seeking Alpha’s Quant Rating on Edgewise Therapeutics Historical earnings data for Edg...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will present at...
Message Board Posts | iCo Therapeutics (OTCMKTS:MSCLF)
Subject | By | Source | When |
---|---|---|---|
50m cash raised. Something brewing! | Oloo | investorshub | 04/20/2023 12:55:04 AM |
News on the go ! | Oloo | investorshub | 04/14/2022 2:28:13 PM |
On the way for a lead candidate: | Oloo | investorshub | 03/31/2022 4:53:10 PM |
Awesome thing coming soon ! | Oloo | investorshub | 12/14/2021 3:09:15 PM |
Effective Dec. 10,2021 ICOTF will change to MSCLF. | Renee | investorshub | 12/09/2021 3:04:03 PM |
News, Short Squeeze, Breakout and More Instantly...
iCo Therapeutics Company Name:
MSCLF Stock Symbol:
OTCMKTS Market:
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will present at...
- Engaged CRO for first-in-human SAT-3247 Phase 1 clinical study - Initiated GLP toxicity studies and GMP manufacturing of SAT-3247 - Continues to be on track to initiate first-in-human clinical trials mid-2024 - Cash balance of $39.6 million as at December 31, 2023 ...
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that Frank Gleeson, cofounder an...